Trastuzumab Suppliers & Bulk Manufacturers
Available Forms: IV & SQ Injection
Available Strengths: IV : 150 mg/ 7.5 mL (vial); SQ: 600 mg/ 5 mL (syringe)
Reference Brands: Herceptin® (EU & US); Herceptin Hylecta® (subcutaneous formulation)
Category: Oncology Cancer Care
Trastuzumab (Herceptin®) is a monoclonal antibody used to treat HER2-positive breast and gastric cancer. It targets the HER2 receptor, inhibiting cancer cell growth. Available in intravenous (IV) and subcutaneous (SC) formulations, it comes in 150 mg vials (IV) and 600 mg syringes (SC). Widely used in combination therapy, it improves outcomes for HER2-positive cancers in both the US and EU. Trastuzumab is available in IV & SQ Injection and strengths such as IV : 150 mg/ 7.5 mL (vial); SQ: 600 mg/ 5 mL (syringe). Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Trastuzumab is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Trastuzumab can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Trastuzumab is a monoclonal antibody used in oncology, primarily for the treatment of HER2-positive breast cancer and gastric cancer. It works by targeting the HER2 receptor, a protein that is overexpressed in some cancer cells, blocking its signaling and inhibiting cancer cell growth. Available as Herceptin® in both the US and EU, Trastuzumab is offered in intravenous (IV) and subcutaneous (SC) formulations. The IV formulation is commonly administered in 150 mg vials, while the SC formulation is available in 600 mg syringes. Used as part of combination therapy, it improves patient outcomes in HER2-positive cancers.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Trastuzumab is used in the treatment of HER2-positive breast cancer, metastatic gastric cancer, and gastroesophageal junction adenocarcinoma. It works by targeting the HER2 receptor on cancer cells, inhibiting their growth and survival.
Trastuzumab is a recombinant humanized monoclonal antibody produced by recombinant DNA technology in mammalian (Chinese Hamster Ovary) cells. It specifically binds to the extracellular domain of the HER2 protein.
Trade names include Herceptin, Ogivri, Herzuma, Trazimera, Ontruzant, and Kanjinti.
Trastuzumab was originally developed and marketed by Genentech (a subsidiary of Roche). Several biosimilar versions are now produced by companies such as Mylan, Samsung Bioepis, Amgen, and Celltrion.
The generic name is trastuzumab.
Brand names include Herceptin, Ogivri, Herzuma, Ontruzant, Trazimera, and Kanjinti.
Trastuzumab and its biosimilars are manufactured in multiple WHO-GMP and US FDA-approved facilities located in the United States, Switzerland, South Korea, and India for global distribution.
Related Products
Tafasitamab‑Cxix
Strength:
200 mg
Form: Injection
Reference Brands: Monjuvi (USA), Minjuvi (EU)
View Details
Dordaviprone Hydrochloride
Strength:
125 mg
Form: Capsules
Reference Brands: Modeyso (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
